Jing-Feng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing-Feng Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Hai-Feng Zhang
Department of Cardiology, The Second Affiliated Hospital, Sun Yat-sen University, 510120 Guangzhou, China
1 shared publication- Hai-Feng Zhang
Department of Cardiology, Sun Yat-sen Memory hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Jing-Ting Mai
Department of Cardiology, Sun Yat-sen Memory hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication Lei Lei
First Affiliated Hospital, Guangxi Medical University
1 shared publicationLi-Guang Zhu
First Affiliated Hospital, Guangxi Medical University
1 shared publication- Li-Guang Zhu
Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China
1 shared publication
Latest Publications
- Open Access
- 8 June 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 120
Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress
Interleukin-33 (IL-33) has been linked to chronic heart failure (CHF) in animal studies, but data on serum IL-33 levels in human CHF are not available. We analyzed levels of IL-33 in serum, and investigated the possible role of IL-33 in oxidative stress.
- 8 June 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 120
Open AccessAltered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress
Interleukin-33 (IL-33) has been linked to chronic heart failure (CHF) in animal studies, but data on serum IL-33 levels in human CHF are not available. We analyzed levels of IL-33 in serum, and investigated the possible role of IL-33 in oxidative stress.
- 3 February 2010
- Published by Springer Nature in Molecular Biology Reports
- Vol. 38 (5) , 2933-2938
Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis
The complement factor H (CFH) Y402H (T1277C) gene polymorphism has been reported to be associated with coronary heart disease (CHD), but results were conflicting. To evaluate the role of the variant in CHD, we performed meta-analyses of all available data. Both electronic and manual searches were performed, all relevant studies were identified. ORs with 95% confidential intervals (CI) under codominant (CC versus TT, TC versus TT), dominant (CC + TC versus TT) and recessive (CC versus TT + TC) models were calculated. Publication bias was addressed. Ten studies including 11 cohorts comprising of 29,764 participants were included. No association between the CFH T1227C polymorphism and CHD could be found. (For overall analysis: dominant model, OR = 1.04, 95%CI: 0.97–1.11; recessive model, OR = 1.04, 95%CI: 0.97–1.11; for Caucasian subgroup: OR = 1.08 95%CI: 0.92–1.27; recessive model, OR = 1.03, 95%CI: 0.96–1.11). Two studies reported positive results in separate population (Caucasian study: recessive model, OR = 0.51, 95%CI: 0.30–0.86; Asians study: dominant model, OR = 2.37, 95%CI: 1.13–4.96). Current evidence do not support the association between the CFH T1277C polymorphism and CHD risk among common population. The association, which could be influenced by CHD onset age, CHD risk factors status and genetics backgrounds, might be significant in some population. More studies on different CHD onset ages and risk factor status should be encouraged.
- 3 February 2010
- Published by Springer Nature in Molecular Biology Reports
- Vol. 38 (5) , 2933-2938
Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis
The complement factor H (CFH) Y402H (T1277C) gene polymorphism has been reported to be associated with coronary heart disease (CHD), but results were conflicting. To evaluate the role of the variant in CHD, we performed meta-analyses of all available data. Both electronic and manual searches were performed, all relevant studies were identified. ORs with 95% confidential intervals (CI) under codominant (CC versus TT, TC versus TT), dominant (CC + TC versus TT) and recessive (CC versus TT + TC) models were calculated. Publication bias was addressed. Ten studies including 11 cohorts comprising of 29,764 participants were included. No association between the CFH T1227C polymorphism and CHD could be found. (For overall analysis: dominant model, OR = 1.04, 95%CI: 0.97–1.11; recessive model, OR = 1.04, 95%CI: 0.97–1.11; for Caucasian subgroup: OR = 1.08 95%CI: 0.92–1.27; recessive model, OR = 1.03, 95%CI: 0.96–1.11). Two studies reported positive results in separate population (Caucasian study: recessive model, OR = 0.51, 95%CI: 0.30–0.86; Asians study: dominant model, OR = 2.37, 95%CI: 1.13–4.96). Current evidence do not support the association between the CFH T1277C polymorphism and CHD risk among common population. The association, which could be influenced by CHD onset age, CHD risk factors status and genetics backgrounds, might be significant in some population. More studies on different CHD onset ages and risk factor status should be encouraged.